Report Detail

Pharma & Healthcare Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review

  • RnM3517465
  • |
  • 11 June, 2019
  • |
  • Global
  • |
  • 57 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The company’s products focus on various therapeutic areas, including, cancer, pain, infections and immunology among others. Its research and development activities involve peptides, proteins, antibodies, small molecule drugs and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics Key Recent Developments

May 08,2019: Nektar Therapeutics reports financial results for the first quarter of 2019
Feb 28,2019: Nektar Therapeutics reports fourth quarter and year-end 2018 financial results
Nov 14,2018: Nektar appoints Wei Lin, M.D., as Senior Vice President of clinical development and Head of Nektar's oncology programs
Nov 07,2018: Nektar Therapeutics reports financial results for the third quarter of 2018
Sep 01,2018: Nektar Therapeutics strengthens Board of Directors with appointment of Veteran Biotechnology Executive Karin Eastham

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents

      List of Tables

        List of Figures

          Section 1 - About the Company

            Nektar Therapeutics - Key Facts

              Nektar Therapeutics - Key Employees

                Nektar Therapeutics - Key Employee Biographies

                  Nektar Therapeutics - Major Products and Services

                    Nektar Therapeutics - History

                      Nektar Therapeutics - Company Statement

                        Nektar Therapeutics - Locations And Subsidiaries

                          Head Office

                            Other Locations & Subsidiaries

                              Section 2 – Company Analysis

                                Company Overview

                                  Nektar Therapeutics - Business Description

                                    Geographical Segment: Europe

                                      Performance

                                        Geographical Segment: United States

                                          Performance

                                            Nektar Therapeutics - Corporate Strategy

                                              Nektar Therapeutics - SWOT Analysis

                                                SWOT Analysis - Overview

                                                  Nektar Therapeutics - Strengths

                                                    Nektar Therapeutics - Weaknesses

                                                      Nektar Therapeutics - Opportunities

                                                        Nektar Therapeutics - Threats

                                                          Nektar Therapeutics - Key Competitors

                                                            Section 3 – Company Financial Ratios

                                                              Financial Ratios - Capital Market Ratios

                                                                Financial Ratios - Annual Ratios

                                                                  Performance Chart

                                                                    Financial Performance

                                                                      Financial Ratios - Interim Ratios

                                                                        Financial Ratios - Ratio Charts

                                                                          Section 4 – Company’s Lifesciences Financial Deals and Alliances

                                                                            Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

                                                                              Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

                                                                                Nektar Therapeutics, Recent Deals Summary

                                                                                  Section 5 – Company’s Recent Developments

                                                                                    May 08, 2019: Nektar Therapeutics reports financial results for the first quarter of 2019

                                                                                      Feb 28, 2019: Nektar Therapeutics reports fourth quarter and year-end 2018 financial results

                                                                                        Nov 14, 2018: Nektar appoints Wei Lin, M.D., as Senior Vice President of clinical development and Head of Nektar's oncology programs

                                                                                          Nov 07, 2018: Nektar Therapeutics reports financial results for the third quarter of 2018

                                                                                            Sep 01, 2018: Nektar Therapeutics strengthens Board of Directors with appointment of Veteran Biotechnology Executive Karin Eastham

                                                                                              Aug 08, 2018: Nektar Therapeutics reports financial results for the second quarter of 2018

                                                                                                May 10, 2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018

                                                                                                  Mar 01, 2018: Nektar Therapeutics Announces Fourth Quarter And Year-End 2017 Financial Results

                                                                                                    Section 6 – Appendix

                                                                                                      Methodology

                                                                                                        Ratio Definitions

                                                                                                          About GlobalData

                                                                                                            Contact Us

                                                                                                              Disclaimer

                                                                                                              Summary:
                                                                                                              Get latest Market Research Reports on Nektar Therapeutics (NKTR). Industry analysis & Market Report on Nektar Therapeutics (NKTR) is a syndicated market report, published as Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review. It is complete Research Study and Industry Analysis of Nektar Therapeutics (NKTR) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                              Last updated on

                                                                                                              REPORT YOU MIGHT BE INTERESTED

                                                                                                              Purchase this Report

                                                                                                              $500.00
                                                                                                              $1,000.00
                                                                                                              $1,500.00
                                                                                                              399.50
                                                                                                              799.00
                                                                                                              1,198.50
                                                                                                              466.50
                                                                                                              933.00
                                                                                                              1,399.50
                                                                                                              77,775.00
                                                                                                              155,550.00
                                                                                                              233,325.00
                                                                                                              41,665.00
                                                                                                              83,330.00
                                                                                                              124,995.00
                                                                                                              Credit card Logo

                                                                                                              Related Reports


                                                                                                              Reason to Buy

                                                                                                              Request for Sample of this report